Central and peripheral isosexual precocious puberty

Current Opinion in Endocrinology and Diabetes

Volumn 8, Issue 1, 2001, Pages 17-22

  Lebrethon, M C ^a   Bourguignon, J P ^a  

^a CHU SART TILMAN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; GONADORELIN DERIVATIVE; GROWTH HORMONE; HORMONE; LUTEINIZING HORMONE RECEPTOR; SPIRONOLACTONE; TAMOXIFEN; TESTOLACTONE;

BODY HEIGHT; BONE AGE; BREAST DEVELOPMENT; CLINICAL FEATURE; DESENSITIZATION; DIAGNOSTIC IMAGING; DIAGNOSTIC PROCEDURE; DISEASE CLASSIFICATION; DRUG EFFECT; DRUG INDUCED DISEASE; FAMILY HISTORY; HUMAN; PATHOGENESIS; PRECOCIOUS PUBERTY; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0035145521     PISSN: 10683097     EISSN: None     Source Type: Journal    
DOI: 10.1097/00060793-200102000-00004     Document Type: Review

References (55)

1. Reexamination of the age limit for defining when puberty is precocious in girls in the United States: Implications for evaluation and treatment
2. Secondary sexual characteristics and menses in young girls seen in office practice: A study from the Pediatrics Research in Office Settings Network
3. Clinical longitudinal standards for height and height velocity for North American children
4. Validity of self-assessment of pubertal maturation in African American and European American adolescents
5. Some hypothalamic hamartomas contain transforming growth factor α, a puberty-inducing growth factor, but not Luteinizing Hormone-Releasing Hormone neurons
6. Cocaine and amphetamine-regulated-transcript peptide mediation of leptin stimulatory effect on the rat Gonadotropin Releasing Hormone pulse generator in vitro
7. Leptin binding activity changes with age: The link between leptin and puberty
8. The impact of reversible gonadal sex steroid suppression on serum leptin concentrations in children with central precocious puberty
9. Serum leptin levels in patients with progressive central precocious puberty
10. Effects of recombinant leptin therapy in a child with congenital leptin deficiency
11. Menarcheal age and growth pattern of Indian girls adopted in Sweden
12. A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty
13. Cosegregation of missense mutations of the luteinizing hormone receptor gene with familial male-limited precocious puberty
14. Genetic heterogeneity of constitutively activating mutations of the human luteinizing hormone receptor in familial male-limited precocious puberty
15. A limited repertoire of mutations of the luteinizing hormone receptor gene in familial and sporadic patients with male LH-independent precocious puberty
16. Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor
17. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome
18. Activating Gsα mutations: Analysis of 43 DNAs from patients presenting signs of McCune-Albright syndrome - A collaborative study
19. Recurrent ovarian cyst and mutation of the Gsα gene in ovarian cyst fluid cells: What is the link with McCune-Albright syndrome?
20. Follow-up of precocious pseudopuberty associated with isolated ovarian follicular cysts
21. Mutation analysis of the follicle-stimulating hormone receptor gene in girls with gonadotropin-independent precocious puberty resulting from autonomous cystic ovaries
22. Activating mutation of the stimulatory G protein as a putative cause of ovarian and testicular human stromal Leydic cell tumors
23. Pelvic ultrasonography: Early differentiation between isolated premature thelarche and central precocious puberty
24. Pelvic ultrasound findings in different forms of sexual precocity
25. Pelvic ultrasonography in normal girls and in girls with pubertal precocity
26. Estrogen levels in girls with premature thelarche compared with normal prepubertal girls as determined by an ultrasensitive recombinant cell bioassay
27. Use of an ultrasensitive recombinant cell bioassay to determine estrogen levels in girls with precocious puberty treated with a Luteinizing Hormone-Releasing Hormone agonist
28. Gonadotropin secretory dynamics during puberty in normal girls and boys
29. Diagnostic value of fluorometric assays in the evaluation of precocious puberty
30. Premature thelarche and central precocious puberty: The relation between clinical presentation and the gonadotropin response to Luteinizing Hormone-Releasing Hormone
31. Precocious puberty in girls: Early diagnosis of a slowly progressing variant
32. Unsustained or slowly progressive puberty in young girls: Initial presentation and long-term follow-up of 20 untreated patients
33. Progression of premature thelarche to central precocious puberty
34. Isolated premature thelarche and thelarche variant: Clinical and auxological follow-up of 119 girls
35. A single sample subcutaneous Luteinizing Hormone-releasing Hormone stimulation test for monitoring LH suppression in children with central precocious puberty receiving LHRH agonists
36. Central precocious puberty: A single blood sample after Gonadotropin-releasing hormone agonist administration in monitoring treatment
37. Auxological and biochemical evaluation of pubertal suppression with the GnRH agonist leuprolide acetate in early and precocious puberty
38. Editorial: Precocious puberty: Who has it? Who should be treated?
39. Preserving adult height potential in girls with idiopathic true precocious puberty
40. Long-term outcome after depot Gonadotropin-releasing hormone agonist treatment of central precocious puberty: Final height, body proportions, body composition, bone mineral density and reproductive function
41. Final height after long-term treatment with triptorelin slow release for central precocious puberty: Importance of statural growth after interruption of treatment
42. Randomised trial of LHRH analogue treatment on final height in girls with onset of puberty aged 7.5-8.5 years
43. Lack of effect of GnRH agonists on final height in girls with advanced puberty: A randomized long-term pilot study
44. Combined use of growth hormone and Gonadotropin-releasing hormone analogues in precocious puberty: Theoretic and practical considerations
45. Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females
46. Bone mineral density and body composition before and during treatment with Gonadotropin-Releasing Hormone agonist in children with central precocious and early puberty
47. Prevention of bone demineralization by calcium supplementation in precocious puberty during Gonadotropin-releasing hormone agonist treatment
48. Reproductive axis after discontinuation of Gonadotropin-releasing hormone analog treatment of girls with precocious puberty: Long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty
49. Longitudinal study of behavioral and affective patterns in girls with central precocious puberty during long-acting triptorelin therapy
50. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset
51. Ketoconazole in the management of precocious puberty not responsive to LHRH-analogue therapy
52. Long term testolactone therapy for precocious puberty in girls with the McCune-Albright syndrome
53. Tamoxifen treatment of progressive precocious puberty in a patient with McCune-Albright syndrome